Holen Sie sich die Stockscreener-App
46.92
0.80%
-0.38
Handel nachbörslich:
47.78
0.86
+1.83%
Schlusskurs vom Vortag:
$47.30
Offen:
$47.13
24-Stunden-Volumen:
727.24K
Relative Volume:
1.17
Marktkapitalisierung:
$3.59B
Einnahmen:
$677.56M
Nettoeinkommen (Verlust:
$59.01M
KGV:
62.95
EPS:
0.7453
Netto-Cashflow:
$136.42M
1W Leistung:
-4.13%
1M Leistung:
+2.49%
6M Leistung:
+23.83%
1J Leistung:
+126.78%
1-Tages-Spanne:
$45.60
$47.78
1-Wochen-Bereich:
$44.40
$49.87
52-Wochen-Spanne:
$19.62
$50.03
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
46.92 | 3.60B | 677.56M | 59.01M | 136.42M | 0.7453 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-09-29 | Eingeleitet | TD Cowen | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
| 2020-06-29 | Bestätigt | BofA Securities | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-12-12 | Bestätigt | Wedbush | Outperform |
| 2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
KNSA SEC FilingsKiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms - Stock Titan
Kiniksa Pharmaceuticals (KNSA) Shows High Growth Momentum and Technical Breakout Potential - ChartMill
Insider Sell: Michael Megna Sells Shares of Kiniksa Pharmaceuticals International PLC - GuruFocus
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Sells 6,625 Shares of Stock - MarketBeat
Kiniksa (KNSA) CAO sells 6,625 shares in Rule 10b5-1 trade - Stock Titan
COO share sale: Kiniksa (KNSA) executive sells 1,703 shares under plan - Stock Titan
If You Invested $1,000 in Kiniksa Pharmaceuticals International, plc (KNSA) - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ: KNSA) Form 144 shows proposed Class A sales - Stock Titan
Kiniksa (KNSA) Form 144: 6,625 Class A shares tied to restricted stock lapses - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $114,988.86 in Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Barry Quart Sells 6,901 Shares - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sanj Patel Sells 7,278 Shares - MarketBeat
Insider Selling: Ross Moat Sells Shares of Kiniksa Pharmaceutica - GuruFocus
Kiniksa (NASDAQ: KNSA) CSO exercises RSUs; 846 shares withheld for tax - Stock Titan
Kiniksa (NASDAQ: KNSA) CFO exercises 2,694 RSUs, covers tax with shares - Stock Titan
Kiniksa (KNSA) CEO Sanj K. Patel exercises options and sells 7,278 shares - Stock Titan
Kiniksa (KNSA) CMO exercises 2,497 RSUs; 1,208 shares withheld - Stock Titan
Kiniksa (KNSA) COO executes RSU exercise and 2,367-share sale under 10b5-1 plan - Stock Titan
Kiniksa (KNSA) CAO nets shares after 3,932 RSUs vest and 1,666 withheld for taxes - Stock Titan
Kiniksa (KNSA) director Quart exercises options and sells 6,901 shares under 10b5-1 plan - Stock Titan
KNSA Launches Heart's Home Campaign for Arcalyst - GuruFocus
Kiniksa targets 40,000 U.S. patients with new ARCALYST TV ads - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month HighStill a Buy? - MarketBeat
Aberdeen Group plc Buys 241,876 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - Defense World
219,591-share cashless exercise reported by Kiniksa (NASDAQ: KNSA) - Stock Titan
Kiniksa (NASDAQ: KNSA) reports 20,000-share cashless exercise sale - Stock Titan
Kiniksa (NASDAQ: KNSA) files Form 144 to sell 2,367 vested shares - Stock Titan
KNSA PE Ratio & Valuation, Is KNSA Overvalued - Intellectia AI
[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity - Stock Titan
Kiniksa (KNSA) CFO receives new options, RSUs and PSUs in 2026 award - Stock Titan
Kiniksa (NASDAQ: KNSA) CEO awarded options, RSUs and PSUs, covers tax - Stock Titan
Kiniksa (KNSA) CMO granted options, RSUs and PSUs in equity awards - Stock Titan
Kiniksa (KNSA) COO receives major equity awards and exercises RSUs - Stock Titan
Kiniksa (KNSA) CAO receives options, RSUs, PSUs and adds to shareholdings - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the Minervini Trend Template with High-Growth Momentum - ChartMill
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Kiniksa Pharmaceuticals International, plc (KNSA) stock price, news, quote and history - Yahoo Finance Singapore
KNSA Should I Buy - Intellectia AI
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year HighShould You Buy? - MarketBeat
Hennion & Walsh Asset Management Inc. Trims Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa's discounted P/S ratio reflects investor caution amid weak growth forecasts. Sentiment may not turn bullish unless the company delivers stronger-than-expected revenue growth. - Moomoo
JPMorgan Chase & Co. Has $7.47 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Vanguard realignment leads to 0-share filing for Kiniksa (KNSA) - Stock Titan
SG Americas Securities LLC Has $22.33 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International PLC (KNSA) Trading 3.48% H - GuruFocus
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a High-Growth Momentum Setup - ChartMill
Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance - msn.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top GARP Investment - ChartMill
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Pullback - Yahoo Finance
Kiniksa Pharmaceuticals International, plc Q4 2025 earnings preview - MSN
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):